Clinical and Angiographic Risk Stratification and Differential Impact on Treatment Outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial

被引:47
作者
Brooks, Maria Mori [1 ]
Chaitman, Bernard R. [2 ]
Nesto, Richard W. [3 ]
Hardison, Regina M.
Feit, Frederick [4 ]
Gersh, Bernard J. [5 ]
Krone, Ronald J. [6 ]
Sako, Edward Y. [7 ]
Rogers, William J. [8 ]
Garber, Alan J. [9 ]
King, Spencer B., III [10 ]
Davidson, Charles J. [11 ]
Ikeno, Fumiaki [12 ]
Frye, Robert L. [5 ]
机构
[1] Univ Pittsburgh, Dept Epidemiol, GSPH, Pittsburgh, PA 15261 USA
[2] St Louis Univ, Sch Med, St Louis, MO USA
[3] Lahey Clin Fdn, Burlington, MA USA
[4] NYU, Sch Med, New York, NY USA
[5] Mayo Clin, Rochester, MN USA
[6] Washington Univ, St Louis, MO USA
[7] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[8] Univ Alabama Birmingham, Birmingham, AL USA
[9] Baylor Coll Med, Houston, TX 77030 USA
[10] St Josephs Heart & Vasc Inst, Atlanta, GA USA
[11] Northwestern Univ, Chicago, IL 60611 USA
[12] Stanford Univ, Stanford, CA 94305 USA
关键词
coronary artery disease; coronary disease; diabetes mellitus; PERCUTANEOUS CORONARY INTERVENTION; ARTERY-DISEASE; FOLLOW-UP; SURGERY; SURVIVAL; MELLITUS; ANGINA;
D O I
10.1161/CIRCULATIONAHA.112.092973
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial assigned patients with type 2 diabetes mellitus to prompt coronary revascularization plus intensive medical therapy versus intensive medical therapy alone and reported no significant difference in mortality. Among patients selected for coronary artery bypass graft surgery, prompt coronary revascularization was associated with a significant reduction in death/myocardial infarction/stroke compared with intensive medical therapy. We hypothesized that clinical and angiographic risk stratification would affect the effectiveness of the treatments overall and within revascularization strata. Methods and Results-An angiographic risk score was developed from variables assessed at randomization; independent prognostic factors were myocardial jeopardy index, total number of coronary lesions, prior coronary revascularization, and left ventricular ejection fraction. The Framingham Risk Score for patients with coronary disease was used to summarize clinical risk. Cardiovascular event rates were compared by assigned treatment within high-risk and low-risk subgroups. Overall, no outcome differences between the intensive medical therapy and prompt coronary revascularization groups were seen in any risk stratum. The 5-year risk of death/myocardial infarction/stroke was 36.8% for intensive medical therapy compared with 24.8% for prompt coronary revascularization among the 381 coronary artery bypass graft surgery-selected patients in the highest angiographic risk tertile (P=0.005); this treatment effect was amplified in patients with both high angiographic and high Framingham risk (47.3% intensive medical therapy versus 27.1% prompt coronary revascularization; P=0.010; hazard ratio=2.10; P=0.009). Treatment group differences were not significant in other clinical-angiographic risk groups within the coronary artery bypass graft surgery stratum, or in any subgroups within the percutaneous coronary intervention stratum. Conclusion-Among patients with diabetes mellitus and stable ischemic heart disease, a strategy of prompt coronary artery bypass graft surgery significantly reduces the rate of death/myocardial infarction MI/stroke in those with extensive coronary artery disease or impaired left ventricular function.
引用
收藏
页码:2115 / +
页数:24
相关论文
共 24 条
  • [1] Modifications of coronary risk factors
    Albu, Jeanine
    Gottlieb, Sheldon H.
    August, Phyllis
    Nesto, Richard W.
    Orchard, Trevor J.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (12A) : 41G - 52G
  • [2] A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
    Frye R.L.
    August P.
    Brooks M.M.
    Hardison R.M.
    Kelsey S.F.
    MacGregor J.M.
    Orchard T.J.
    Chaitman B.R.
    Genuth S.M.
    Goldberg S.H.
    Hlatky M.A.
    Jones T.L.Z.
    Molitch M.E.
    Nesto R.W.
    Sako E.Y.
    Sobel B.E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (24) : 2503 - 2515
  • [3] Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial
    Barsness, Gregory W.
    Gersh, Bernard J.
    Brooks, Maria Mori
    Frye, Robert L.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (12A) : 31G - 40G
  • [4] Optimal medical therapy with or without PCI for stable coronary disease
    Boden, William E.
    O'Rourke, Robert A.
    Teo, Koon K.
    Hartigan, Pamela M.
    Maron, David J.
    Kostuk, William J.
    Knudtson, Merril
    Dada, Marcin
    Casperson, Paul
    Harris, Crystal L.
    Chaitman, Bernard R.
    Shaw, Leslee
    Gosselin, Gilbert
    Nawaz, Shah
    Title, Lawrence M.
    Gau, Gerald
    Blaustein, Alvin S.
    Booth, David C.
    Bates, Eric R.
    Spertus, John A.
    Berman, Daniel S.
    Mancini, G. B. John
    Weintraub, William S.
    Boden, W.
    O'Rourke, R.
    Teo, K.
    Hartigan, P.
    Weintraub, W.
    Maron, D.
    Mancini, J.
    Weintraub, W.
    Boden, W.
    O'Rourke, R.
    Teo, K.
    Hartigan, P.
    Knudtson, M.
    Maron, D.
    Bates, E.
    Blaustein, A.
    Booth, D.
    Carere, R.
    Ellis, S.
    Gosselin, G.
    Gau, G.
    Jacobs, A.
    King, S., III
    Kostuk, W.
    Harris, C.
    Spertus, J.
    Peduzzi, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (15) : 1503 - 1516
  • [5] Impact of Optimal Medical Therapy With or Without Percutaneous Coronary Intervention on Long-Term Cardiovascular End Points in Patients With Stable Coronary Artery Disease (from the COURAGE Trial)
    Boden, William E.
    O'Rourke, Robert A.
    Teo, Koon K.
    Maron, David J.
    Hartigan, Pamela M.
    Sedlis, Steven P.
    Dada, Marcin
    Labedi, Mohammed
    Spertus, John A.
    Kostuk, William J.
    Berman, Daniel S.
    Shaw, Leslee J.
    Chaitman, Bernard R.
    Mancini, G. B. John
    Weintraub, William S.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (01) : 1 - 4
  • [6] Brooks MM, 2008, AM HEART J, V156, P528, DOI [10.1016/j.ajh.2008.05.015, 10.1016/j.ahj.2008.05.015]
  • [7] Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial
    Brooks, Maria Mori
    Frye, Robert L.
    Genuth, Saul
    Detre, Katherine M.
    Nesto, Richard
    Sobel, Burton E.
    Kelsey, Sheryl F.
    Orchard, Trevor J.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (12A) : 9G - 19G
  • [8] The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction
    Chaitman, Bernard R.
    Hardison, Regina M.
    Adler, Dale
    Gebhart, Suzanne
    Grogan, Mary
    Ocampo, Salvador
    Sopko, George
    Ramires, Jose A.
    Schneider, David
    Frye, Robert L.
    [J]. CIRCULATION, 2009, 120 (25) : 2529 - U44
  • [9] COX DR, 1972, J R STAT SOC B, V34, P187
  • [10] Primary and subsequent coronary risk appraisal: New results from The Framingham Study
    D'Agostino, RB
    Russell, MW
    Huse, DM
    Ellison, RC
    Silbershatz, H
    Wilson, PWF
    Hartz, SC
    [J]. AMERICAN HEART JOURNAL, 2000, 139 (02) : 272 - 281